Entelon Tab. not checked
Hanlim Pharm. Co., Ltd. · Vitis Vinifera Seed Dreid Extract 50mg · Vitis Vinifera Seed Dreid Extract 150mg
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “twice daily for 8 weeks(with Venitol Tab. It is for the masking.)”In the company’s words, NCT04882228 on ClinicalTrials.gov
- Tested for
- Chronic Venous Disease, Non Proliferative Diabetic Retinopathy
- Main trialPhase 4
- “This clinical trial is a multi-center, double-blind, randomized, active controlled , parallel design, non-inferiority phase 4 study to evaluate the efficacy and safety of Entelon 150mg in 278 patients with chronic venous disease.”In the company’s words, NCT04882228 on ClinicalTrials.gov
- Other names
- Vitis Vinifera Seed Dreid Extract 50mg · Vitis Vinifera Seed Dreid Extract 150mg
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Unknown | 28 Feb 2022 | Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD) | |
| Phase 4Unknown | 16 Dec 2024 | Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026